Latest Breaking News On - Sternir inc - Page 8 : comparemela.com

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerAlex loboInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (

United statesMiltonh wernerAlex loboInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesAlex loboMiltonh wernerInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Present at the International Conference on Alzheimer s and Parkinson s Diseases and related neurological disorders

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesVastra gotalands lanMiltonh wernerAlex loboMilton wernerCompany phaseInhibikase therapeutics incCompany contactInternational conference on alzheimerDrug developmentExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesChief executive officer

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboInhibikase therapeutics incCompany contactExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesMultiple system atrophyChronic myelogenousAbelson tyrosine kinaseAbleson tyrosinePrivate securities litigation reform actHealth care amp hospitals